(27/01/22 from 18:00 - 19:00)
Time: 6.00PM CET (5.00PM UK time)
The aim of this webinar is to revisit latest evidence on secondary preventive effect of SGLT2 inhibitor drugs.
This activity has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1 European CME credits (ECMEC®s)
The key learning objectives will be;
- To discuss the cardioprotective effects of SGLT2 inhibitors in terms of heart failure.
- To discuss the effect of SGLT2 inhibitors on kidney function
|WelcomeLearning objectivesIntro/Bio Speakers||Dr. Samuel Seidu, chair (U.K.)|
|Heart failure and SGLT2 inhibitor therapy beyond the presence of diabetes||Dr. Xavier Garcia Moll (ES)|
|SGLT2 inhibitors and the kidney: matter of controversy||Dr.David Wheeler (UK)|
|Question and answers||All|
Add this event to your calendar: or as iCal